Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Biotechnology

Healthcare
$0.80 -5.22%

-$0.04 today

Market cap
$52.19M
Beta
0.76
P/E (TTM)
-4.6
EPS (TTM)
-$0.16
52W Low $0.39High $3.87

Volume 0.23M

Average 1.15M

RANI Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Rani Therapeutics Holdings, Inc.NASDAQ: RANI

Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026

Weighted avg shares growth accelerates

Q1 FY2026 weighted avg shares of 180M shares rose 438.3% year over year, ahead of the +230.0% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 22.4% from the prior quarter. Over 3 fiscal years it compounded at +40.6% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +438.3% holds above the trailing-twelve-month pace of +230.0%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
180M+22.4% QoQ
Last fiscal yearDec 2025
66.14M+132.3% YoY
LTMMar 2026
100.04M+230.0% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+438.3%——
1 year+132.3%——
3-year CAGR+40.6%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
66.14M USD
Year-over-year change
+132.3%
4-year CAGR
+35.6%

Weighted Avg Shares vs competitors

How RANI compares with its peers on the latest reported figures

  • RANI's LTM Mar 2026 weighted avg shares of 100.04M shares is the 2nd highest of the 9 companies compared; the peer median is 52.29M shares.
  • Its year-over-year change of +230.0% is the highest of 9, against a peer median of +31.5%.
  • Over three fiscal years its annual growth of +40.6% compares with a peer median of +23.7%.
RANI Competitors Peer median
Weighted Avg Shares for RANI and competitors
Company Period LTM YoY 3-year CAGR
SGMOSangamo Therapeutics, Inc.LTM Mar 2026322.14M +52.9%+22.0%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026100.04M +230.0%+40.6%
IPHAInnate Pharma S.A.FY202589.42M +10.3%+4.0%
MISTMilestone Pharmaceuticals Inc.LTM Mar 202686.73M +33.0%+25.5%
CRDFCardiff Oncology, Inc.LTM Mar 202667.15M +30.5%+15.3%
MOLNMolecular Partners AGLTM Mar 202637.43M +9.0%+4.7%
ELTXElicio Therapeutics, Inc.LTM Mar 202616.57M +32.5%+70.3%
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 202612.8M +30.5%+47.3%
TNXPTonix Pharmaceuticals Holding Corp.LTM Mar 20269.62M +108.1%+40.5%
Peer median (excluding RANI) 52.29M+31.5%+23.7%

Competitors are the stored peer set for RANI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.72M001.03M1.63M
Cost of Revenue00822K0900K
Gross Profit2.72M0(822K)1.03M733K
Gross Margin100.0%——100.0%44.9%
Research & Development26.48M36.61M39.62M26.68M20.21M
Selling, General & Admin27.83M26.84M26.48M23.95M19.74M
Operating Expenses54.32M63.45M65.28M54.34M39.04M
Depreciation & Amortization497K548K822K1.03M900K
EBITDA(52.08M)(61.66M)(61.98M)(50.52M)(37.16M)
EBITDA Margin-1917.0%——-4914.7%-2275.5%
Operating Income(51.6M)(63.45M)(66.1M)(53.31M)(38.31M)
Operating Margin-1899.1%——-5186.2%-2346.0%
Interest Income89K1.25M3.3M1.76M827K
Interest Expense466K1.07M5.09M5.03M2.89M
Other Income / Expenses(1.45M)177K(1.78M)23.3M(2.64M)
Income Before Tax(53.05M)(63.27M)(67.88M)(30.02M)(40.95M)
Pre-Tax Margin-1952.4%——-2920.0%-2507.7%
Income Tax Expense41K70K026.57M0
Net Income(8.33M)(30.59M)(33.97M)(30.02M)(29.67M)
Net Margin-306.6%——-2920.0%-1817.1%
EPS (Basic)(0.42)(1.28)(1.33)(1.05)(0.45)
EPS (Diluted)(0.42)(1.28)(1.33)(1.05)(0.45)
Weighted Avg Shares19.53M23.82M25.51M28.48M66.14M
Weighted Avg Shares (Diluted)19.53M23.82M25.51M28.48M66.14M

Rani Therapeutics Holdings, Inc.

NASDAQ:RANI

Intrinsic Alpha fair value

Locked

Current Price

$0.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.